Literature DB >> 3755306

Elimination of atracurium in humans: contribution of Hofmann elimination and ester hydrolysis versus organ-based elimination.

D M Fisher, P C Canfell, M R Fahey, J I Rosen, S M Rupp, L B Sheiner, R D Miller.   

Abstract

Atracurium, a nondepolarizing muscle relaxant, is eliminated through several pathways, including Hofmann elimination (spontaneous degradation in plasma and tissue at normal body pH and temperature) and ester hydrolysis (catalysis by nonspecific esterases). Because elimination of atracurium occurs in both tissue and plasma, traditional pharmacokinetic models assuming elimination from a single central compartment are inaccurate for atracurium. The authors developed a two-compartment pharmacokinetic model in which hepatic and/or renal elimination occurs from the central compartment (Cl organ), and Hofmann elimination and ester hydrolysis occur from both central and peripheral compartments (Cl nonorgan). To determine the in vitro rate constant for Hofmann elimination and ester hydrolysis, atracurium was added to whole blood kept at each patient's pH and temperature. The values for this rate constant ranged from 0.0193 to 0.0238 per min. When these values were applied to the pharmacokinetic model, Cl total, Cl organ, and Cl nonorgan were 4.8 +/- 1.1, 3.0 +/- 0.9, and 1.9 +/- 0.6 ml . kg-1 . min-1, respectively. The authors conclude that more than one-half of the clearance of atracurium occurs via pathways other than Hofmann elimination and ester hydrolysis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3755306

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  16 in total

1.  Peripheral link model as an alternative for pharmacokinetic-pharmacodynamic modeling of drugs having a very short elimination half-life.

Authors:  J Laurin; F Donati; F Nekka; F Varin
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-02       Impact factor: 2.745

2.  Assuming peripheral elimination: its impact on the estimation of pharmacokinetic parameters of muscle relaxants.

Authors:  J Laurin; F Nekka; F Donati; F Varin
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

Review 3.  Clinical pharmacokinetics of the newer neuromuscular blocking drugs.

Authors:  D P Atherton; J M Hunter
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 4.  Antiepileptic-induced resistance to neuromuscular blockers: mechanisms and clinical significance.

Authors:  Sulpicio G Soriano; J A Jeevendra Martyn
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of neuromuscular relaxants in pregnancy.

Authors:  J Guay; Y Grenier; F Varin
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

7.  Atracurium, pharmacokinetics and metabolites.

Authors:  F Donati
Journal:  Can J Anaesth       Date:  1989-05       Impact factor: 5.063

8.  Dose requirements of continuous infusion of rocuronium and atracurium throughout orthotopic liver transplantation in humans.

Authors:  Xiao-Chuan Weng; Liang Zhou; Yin-Yan Fu; Sheng-Mei Zhu; Hui-Liang He; Jian Wu
Journal:  J Zhejiang Univ Sci B       Date:  2005-09       Impact factor: 3.066

Review 9.  Clinical pharmacokinetics of cisatracurium besilate.

Authors:  D F Kisor; V D Schmith
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

Review 10.  Selecting neuromuscular-blocking drugs for elderly patients.

Authors:  Tristan M Cope; Jennifer M Hunter
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.